Access to treatment is a universal right, and it is an indispensable element to the fulfillment of our right to health.
The Peruvian State, by constitutional mandate, is obliged to ensure the fulfilment of this right. For this reason, different organizations of civil society in Peru, including AID FOR AIDS Peru, call on the Peruvian Government in relation to the over-expenditure perceived in March of this year. Such expenditure exceeds 21 million soles (equivalent to more than $ 7 million) for the acquisition of Atazanavir 300 mg (300 mg Reyataz ®), which is used as one of the options for the treatment of HIV. This over-expenditure represents more than 50% of the budget allocated for the purchase of ARVs in the MINSA and EsSalud (Social Security). The lack of timely decisions in Peru has made that public health agencies pay up to 20 times over the price paid for the generic version of this medication compared to Bolivia.
For 2019, this will lead to a total over-expenditure of 130 million soles (approximately 44 million USD), date in which Bristol Myers Squibb patent will expire.
The immediate license is a legitimate mechanism established in Peruvian legislation and international agreements, and it should be used to allow competition in the market; and thus to reduce the price of medicines, and fight against monopoly, such as the one imposed by the Bristol Myers Squibb Pharmaceutical for its product Reyataz ® (Atazanavir).
For this reason, Peruvians demand to their Government declare of public interest the use of Atazanavir, and demand authorities to grant the license in the terms and conditions established in the legislation.
To access the statement and video click on the links below